###begin article-title 0
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 5 7 5 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C3</italic>
###xml 12 17 12 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARMS2</italic>
CFH, C3 and ARMS2 Are Significant Risk Loci for Susceptibility but Not for Disease Progression of Geographic Atrophy Due to AMD
###end article-title 0
###begin p 1
###xml 97 100 <span type="species:ncbi:11970?0.48717948717948717|species:ncbi:10836?0.02564102564102564">SSV</span>
###xml 153 156 <span type="species:ncbi:11970?0.48717948717948717|species:ncbi:10836?0.02564102564102564">SSV</span>
###xml 246 249 <span type="species:ncbi:11970?0.48717948717948717|species:ncbi:10836?0.02564102564102564">SSV</span>
Conceived and designed the experiments: HPNS UM FGH BHFW. Performed the experiments: HPNS MF LGF SSV AG CNK FM AM DP AWW. Analyzed the data: HPNS MF LGF SSV AG CA CH CNK FM AM DP AWW UM FGH TB BHFW. Contributed reagents/materials/analysis tools: SSV. Wrote the paper: HPNS UM FGH TB BHFW. Obtained funding: BHFW HPNS MF.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 147 150 147 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 177 179 177 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C3</italic>
###xml 227 232 227 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARMS2</italic>
Age-related macular degeneration (AMD) is a prevalent cause of blindness in Western societies. Variants in the genes encoding complement factor H (CFH), complement component 3 (C3) and age-related maculopathy susceptibility 2 (ARMS2) have repeatedly been shown to confer significant risks for AMD; however, their role in disease progression and thus their potential relevance for interventional therapeutic approaches remains unknown.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 50 53 50 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 55 57 55 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C3</italic>
###xml 62 67 62 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARMS2</italic>
###xml 323 326 323 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 336 338 336 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C3</italic>
###xml 352 357 352 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARMS2</italic>
###xml 404 406 404 406 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;9</sup>
###xml 414 416 414 416 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;3</sup>
###xml 432 435 432 435 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;12</sup>
###xml 604 605 604 605 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Here, we analyzed association between variants in CFH, C3 and ARMS2 and disease progression of geographic atrophy (GA) due to AMD. A quantitative phenotype of disease progression was computed based on longitudinal observations by fundus autofluorescence imaging. In a subset of 99 cases with pure bilateral GA, variants in CFH (Y402H), C3 (R102G), and ARMS2 (A69S) are associated with disease (P = 1.6x10-9, 3.2x10-3, and P = 2.6x10-12, respectively) when compared to 612 unrelated healthy control individuals. In cases, median progression rate of GA over a mean follow-up period of 3.0 years was 1.61 mm2/year with high concordance between fellow eyes. No association between the progression rate and any of the genetic risk variants at the three loci was observed (P>0.13).
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
###xml 37 40 37 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 42 44 42 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C3</italic>
###xml 50 55 50 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARMS2</italic>
This study confirms that variants at CFH, C3, and ARMS2 confer significant risks for GA due to AMD. In contrast, our data indicate no association of these variants with disease progression which may have important implications for future treatment strategies. Other, as yet unknown susceptibilities may influence disease progression.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 107 110 107 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Congdon1">[1]</xref>
###xml 467 470 467 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-deJong1">[2]</xref>
###xml 471 474 471 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Jager1">[4]</xref>
###xml 732 735 732 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Friedman1">[5]</xref>
###xml 736 739 736 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Klein2">[7]</xref>
###xml 855 858 855 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Brown1">[8]</xref>
###xml 860 863 860 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Rosenfeld1">[9]</xref>
###xml 462 465 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 528 531 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 815 818 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Age-related macular degeneration (AMD [MIM 603075]) is the leading cause of blindness in Western countries [1]. Two major forms of advanced AMD are responsible for vision loss. Geographic atrophy (GA) or "dry" AMD is characterized by an extensive loss of the choriocapillaris and the overlying retinal pigment epithelium, while the neovascular form or "wet" AMD develops due to invasion of neovascular complexes, a process known as choroidal neovascularization (CNV) [2]-[4]. Although constituting only 10-15% of all AMD cases, CNV accounts for almost 80% of AMD-related blindness. Nevertheless, with an increasingly aging population, blindness due to GA is predicted to become a significant socioeconomic burden in the near future [5]-[7]. To date, successful therapeutic intervention is available only for active CNV, while GA still remains untreatable [8], [9].
###end p 9
###begin p 10
###xml 95 98 95 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-deJong1">[2]</xref>
###xml 100 103 100 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Holz1">[3]</xref>
###xml 105 109 105 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Haddad1">[10]</xref>
###xml 111 115 111 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Scholl1">[11]</xref>
###xml 164 168 164 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Edwards1">[12]</xref>
###xml 169 173 169 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Klein3">[15]</xref>
###xml 184 188 184 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Jakobsdottir1">[16]</xref>
###xml 190 194 190 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Rivera1">[17]</xref>
###xml 565 567 565 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C3</italic>
###xml 587 591 587 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Maller1">[18]</xref>
###xml 593 597 593 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Yates1">[19]</xref>
###xml 714 719 714 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARMS2</italic>
###xml 734 738 734 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Rivera1">[17]</xref>
###xml 740 744 740 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Fritsche1">[20]</xref>
###xml 774 779 774 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 794 798 794 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Dewan1">[21]</xref>
###xml 800 804 800 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Yang1">[22]</xref>
AMD is a complex condition with both genetic and environmental factors contributing to disease [2], [3], [10], [11]. Genetic variants at two chromosomal loci, 1q31 [12]-[15] and 10q26 [16], [17] confer major disease risks, together likely accounting for over 50% of cases. Chromosome 1q31 association is tightly linked to the complement factor H (CFH) gene suggesting an important role of inflammation and the alternative pathway of complement in AMD pathogenesis. This is further supported by strong association of AMD with variants in the complement component 3 (C3 [MIM 120700]) gene [18], [19]. At 10q26, variants at two genes in strong linkage disequilibrium, namely age-related maculopathy susceptibility 2 (ARMS2 [MIM 611313]) [17], [20] and HtrA serine peptidase 1 (HTRA1 [MIM 602194]) [21], [22], were strongly linked to AMD susceptibility. Further studies will be needed however to clarify which of the two candidates plays the causal role in AMD pathology.
###end p 10
###begin p 11
###xml 150 153 150 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 164 169 164 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARMS2</italic>
###xml 254 258 254 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Seddon1">[23]</xref>
###xml 499 502 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Going beyond cross-sectional association between AMD and genetic variants, Seddon et al. reported a significant association between the polymorphisms CFH-Y402H and ARMS2-A69S and progression from early or intermediate stages of AMD to the advanced forms [23]. It should be noted, however, that this study has not addressed the question of whether genetic variants are associated with disease progression once late AMD has developed. Nevertheless, it is the progression of the two late forms, GA and CNV, which is the most important variable with regard to future therapeutic intervention.
###end p 11
###begin p 12
###xml 456 460 456 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Davis1">[24]</xref>
###xml 461 465 461 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Scholl2">[27]</xref>
###xml 936 940 936 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Holz2">[28]</xref>
###xml 1141 1144 1141 1144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 1146 1148 1146 1148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C3</italic>
###xml 1154 1159 1154 1159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARMS2</italic>
###xml 984 992 <span type="species:ncbi:9606">patients</span>
A quantitative measure of geographic atrophy progression represents the detection and quantification of atrophic areas on the fundus at different time points in order to calculate atrophy enlargement rates over time. The gold standard to define such areas has been fundus photography; however, the reproducibility for defining and measuring GA by fundus photography has been reported by several groups to be only moderate, particularly for smaller lesions [24]-[27]. An attractive alternative for non-invasive imaging of atrophy and its progression over time is fundus autofluorescence (FAF) imaging with the confocal scanning laser ophthalmoscope (cSLO). This method potentially allows direct visualization of loss of key cells in the disease process by tracing metabolic RPE changes. Therefore, areas of GA can now reliably be mapped facilitating absolute quantification of atrophic areas and their progression in the disease process [28]. Here, we used FAF imaging for phenotyping patients with GA in a longitudinal study, analyzed GA progression and correlated this biologically-based quantitative phenotype with genetic variants in the CFH, C3, and ARMS2 genes.
###end p 12
###begin title 13
Results
###end title 13
###begin p 14
###xml 333 341 333 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007418.s001">Table S1</xref>
###xml 333 341 333 341 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="supplementary-material" rid="pone.0007418.s001">Table S1</xref></bold>
###xml 14 26 <span type="species:ncbi:9606">participants</span>
###xml 85 88 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 148 156 <span type="species:ncbi:9606">patients</span>
###xml 497 504 <span type="species:ncbi:9606">patient</span>
###xml 535 543 <span type="species:ncbi:9606">patients</span>
###xml 689 697 <span type="species:ncbi:9606">patients</span>
###xml 849 857 <span type="species:ncbi:9606">patients</span>
Among the 619 participants of the FAM study cohort, 136 exhibited GA with no sign of CNV throughout subsequent follow-up examinations. Of these, 99 patients exhibited pure GA in both eyes throughout the study period and were included in the further analysis (for a comprehensive compilation of the phenotypic and genotypic data, see Table S1). Mean follow-up was 3.0 years (SD, 2.1; range, 6 months to 10 years). Mean number of measurements of GA area was 3.3 per eye (range, 2 to 12) and 3.5 per patient (range, 2 to 12). Mean age of patients was 71.8+/-7.4 years (range, 53-89 years) and 76.2+/-5.3 years (range, 65-97 years) for the controls (p<0.0001; t-test). Overall, 61% of the AMD patients and 62% of the controls were female (p = 0.837). Considering the most general measurement of smoking history as a binary "ever or never" variable, AMD patients were significantly more likely to smoke than controls (49% versus 13%; p<0.0001).
###end p 14
###begin p 15
###xml 129 132 129 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 155 160 155 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARMS2</italic>
###xml 190 192 190 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C3</italic>
###xml 243 250 243 250 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 1</bold>
###xml 243 250 243 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007418-t001"><bold>Table 1</bold></xref>
###xml 336 337 336 337 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 452 456 452 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Holz2">[28]</xref>
###xml 543 551 543 551 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1</bold>
###xml 543 551 543 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007418-g001"><bold>Figure 1</bold></xref>
###xml 591 592 591 592 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 763 767 763 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Lin1">[29]</xref>
In a case-control association analysis (N = 99 cases of pure bilateral GA; N = 612 controls), polymorphisms Y402H (rs1061170) in CFH, A69S (rs10490924) in ARMS2 and R102G (rs2230199) in the C3 gene were strongly associated with GA due to AMD (Table 1). In a case-only analysis (N = 99 GA cases), the median growth rate of GA was 1.61 mm2/year (interquartile range [IQR], 1.19 to 2.12; range, 0.26 to 3.45), which is very similar to our previous report [28]. A typical example of serial FAF images over a study period of 109 months is shown in Figure 1. Median GA area at baseline was 6.50 mm2 (IQR, 3.26 to 11.03; range, 0.05 to 34.6). As a measure of concordance of the GA progression rate between the right and left eye, the concordance correlation coefficient [29] was calculated at 0.726, 95% CI [0.587; 0.8297] indicating a high intra-individual symmetry of the GA progression rate in our cohort.
###end p 15
###begin title 16
###xml 23 30 <span type="species:ncbi:9606">patient</span>
Progression of GA in a patient with age-related macular degeneration over a period of nine years.
###end title 16
###begin p 17
###xml 70 71 70 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 104 105 104 105 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 221 222 221 222 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 264 267 264 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 287 293 287 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARMS2-</italic>
###xml 317 319 317 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C3</italic>
###xml 233 240 <span type="species:ncbi:9606">patient</span>
Atrophic areas are outlined in each image. Baseline GA area was 4.3 mm2; GA progression rate was 1.50 mm2/year based on 12 observations within nine years of clinical follow-up. GA growth rate of the fellow eye was 1.59 mm2/year. The patient's genotype was C/T for CFH-rs1061170, G/G for ARMS2-rs10490924, and C/G for C3-rs2230199.
###end p 17
###begin title 18
###xml 26 34 <span type="species:ncbi:9606">patients</span>
SNP association in 99 AMD patients with bilateral pure GA versus 612 matched controls.
###end title 18
###begin p 19
Abbreviations: MAF, minor allele frequency; ATT, Armitage's trend test; CI, confidence interval.
###end p 19
###begin p 20
###xml 76 79 76 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 89 94 89 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARMS2</italic>
###xml 107 109 107 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C3</italic>
###xml 188 196 188 196 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2</bold>
###xml 188 196 188 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007418-g002"><bold>Figure 2</bold></xref>
###xml 295 298 295 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 300 305 300 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARMS2</italic>
###xml 310 312 310 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C3</italic>
###xml 338 345 338 345 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 2</bold>
###xml 338 345 338 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007418-t002"><bold>Table 2</bold></xref>
###xml 664 667 664 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 669 676 669 676 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 2</bold>
###xml 669 676 669 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007418-t002"><bold>Table 2</bold></xref>
###xml 791 792 791 792 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 806 809 806 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 820 821 820 821 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 834 839 834 839 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARMS2</italic>
###xml 853 854 853 854 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 868 870 868 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C3</italic>
###xml 946 947 946 947 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1037 1045 1037 1045 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007418.s002">Table S2</xref>
###xml 1037 1045 1037 1045 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="supplementary-material" rid="pone.0007418.s002">Table S2</xref></bold>
###xml 119 127 <span type="species:ncbi:9606">patients</span>
To visualize the distribution of GA growth rate for individual genotypes of CFH (Y402H), ARMS2 (A69S), and C3 (R102G), patients were grouped for genotypes of these three major risk genes (Figure 2). The association between the quantitative trait variable "GA progression" and SNP alleles in the CFH, ARMS2 and C3 genes was then analyzed (Table 2). Adjusting for age, smoking history and body mass index (BMI), and after a Sidak correction for multiple testing, none of the single-marker P values remained significant at alpha = 0.05. Similarly, there was no significant association between GA progression and the Y402H (rs1061170) and I62V (rs800292) haplotype of CFH (Table 2). Power calculations revealed a power of 80% (at alpha = 0.05) for detecting an additive allele effect of 0.278 mm2/year (Y402H, CFH), 0.275 mm2/year (A69V, ARMS2) and 0.292 mm2/year (R102G, C3), respectively. There was 95% power to detect an effect of less than 0.4 mm2/year for any of the three genetic risk factors. A detailed power calculation is given in Table S2.
###end p 20
###begin title 21
###xml 124 127 124 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 133 138 133 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARMS2</italic>
###xml 148 150 148 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C3</italic>
###xml 60 68 <span type="species:ncbi:9606">patients</span>
Growth rates of geographic atrophy for the subgroups of AMD patients grouped by genotypes for the three major risk alleles, CFH (A), ARMS2 (B), and C3 (C).
###end title 21
###begin p 22
###xml 42 44 42 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th</sup>
###xml 51 53 51 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th</sup>
###xml 83 85 83 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th</sup>
###xml 92 94 92 94 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th</sup>
Shown are the median (central bar), the 25th and 75th percentiles (grey box), the 5th and 95th percentiles (bars) and the minimum and maximum (small circles).
###end p 22
###begin title 23
Association between the quantitative trait variable "geographic atrophy progression" and SNP alleles and haplotypes.
###end title 23
###begin p 24
###xml 107 108 107 108 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Progression rates relative to the reference allele/haplotype (non risk) which was set by definition to 0 mm2/year.
###end p 24
###begin p 25
Testing for a positive trend of progression (one-sided test).
###end p 25
###begin p 26
Sidak correction for five tests (4 SNPs and haplotype test).
###end p 26
###begin p 27
Two-sided test.
###end p 27
###begin title 28
Discussion
###end title 28
###begin p 29
###xml 133 136 133 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 138 140 138 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C3</italic>
###xml 146 151 146 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARMS2</italic>
###xml 274 278 274 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Maller1">[18]</xref>
###xml 280 284 280 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Yates1">[19]</xref>
###xml 286 290 286 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Schaumberg1">[30]</xref>
###xml 445 447 445 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C3</italic>
###xml 534 538 534 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Maller1">[18]</xref>
###xml 540 544 540 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Yates1">[19]</xref>
###xml 576 581 576 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 655 666 655 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARMS2-HTRA1</italic>
###xml 880 884 880 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Rivera1">[17]</xref>
###xml 983 994 983 994 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARMS2-HTRA1</italic>
###xml 1050 1053 1050 1053 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 1058 1063 1058 1063 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARMS2</italic>
###xml 383 386 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 523 526 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 601 604 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 865 868 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Here, we demonstrate a significant association between our study group with late AMD manifestations of pure GA and known variants at CFH, C3, and ARMS2. The odds ratios for heterozygotes and homozygotes for any of the three genes are highly consistent with previous reports [18], [19], [30]. Those reports typically included mixed study populations including both forms of late AMD, CNV and GA. This was also true for recent reports of R102G in C3 as a significant risk variant for AMD where similar results were found for CNV and GA [18], [19]. DeWan and co-workers reported HTRA1 as a risk gene for CNV due to AMD, implicating that polymorphisms in the ARMS2-HTRA1 region are responsible for this specific phenotype of late AMD. This is a surprising notion since others, including our own study, did not find any difference in the association data between GA and CNV due to AMD [17]. Our current data now unambiguously demonstrate that the risk for GA is similarly associated with ARMS2-HTRA1 variants and suggests that the association between the CFH and ARMS2 polymorphisms is independent of disease evolution towards the atrophic or the neovascular form of AMD.
###end p 29
###begin p 30
###xml 97 100 97 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 109 114 109 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARMS2</italic>
###xml 269 270 269 270 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 330 331 330 331 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 667 668 667 668 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
A significant original finding of this study is that none of the AMD-associated polymorphisms in CFH, C3 and ARMS2 contribute to GA progression once GA has developed. It is of note that our analysis had good power to detect an additive allele effect of less than 0.3 mm2 of GA progression per year. A GA progression rate of 0.3 mm2 or less represents a relatively small effect with less than 1/5 of the mean effect in our study population. Moreover, it is clearly below the threshold of recent phase II studies with therapeutic intervention in GA (e.g. fenretinide trial; ClinicalTrials.gov identifier: NCT00429936) which aim to slow GA progression by at least 0.6 mm2/year.
###end p 30
###begin p 31
###xml 641 645 641 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-The1">[31]</xref>
###xml 23 31 <span type="species:ncbi:9606">patients</span>
###xml 253 260 <span type="species:ncbi:9606">patient</span>
###xml 546 554 <span type="species:ncbi:9606">patients</span>
###xml 611 619 <span type="species:ncbi:9606">patients</span>
###xml 690 698 <span type="species:ncbi:9606">patients</span>
Although the number of patients (N = 99; baseline, N = 619) may appear limited, the significance of this study mainly originates from its dependency on the major outcome variable which is a biologically based continuous variable. To put the size of our patient study group into perspective, the major population-based studies such as the Beaver Dam Eye Study as well as the major clinical trial sponsored by the National Eye Institute (e.g. Age-Related Eye Disease Study, AREDS) all include similarly limited numbers of longitudinally phenotyped patients with pure bilateral GA. Specifically, AREDS has 70 such patients (baseline, N = 3640) [31], while the Beaver Dam Eye Study has only 27 patients of at least 5-year follow-up (baseline, N = 4926; Ronald Klein, personal communication).
###end p 31
###begin p 32
###xml 548 552 548 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Holz2">[28]</xref>
###xml 554 558 554 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Dreyhaupt1">[32]</xref>
###xml 629 637 <span type="species:ncbi:9606">patients</span>
The strength of the current data is based on the phenotypic assessment of GA by cSLO-based FA imaging, semi-automated image analysis and complex statistics condensing longitudinal data into one continuous phenotypic variable. Although its accuracy may improve with the number of measurements over time, we have previously shown that GA progression is linear, which makes two consecutive measurements sufficient to estimate GA growth rate, although the number of longitudinal observations improves the accuracy of the estimated GA progression rate. [28], [32] An additional strong point in this study is the substantial number of patients with bilateral pure GA recruited through the multicenter FAM study.
###end p 32
###begin p 33
###xml 46 57 46 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARMS2-HTRA1</italic>
###xml 107 111 107 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARMS</italic>
###xml 113 117 113 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Jakobsdottir1">[16]</xref>
###xml 119 123 119 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Rivera1">[17]</xref>
###xml 128 133 128 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 133 137 133 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Dewan1">[21]</xref>
###xml 139 143 139 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Yang1">[22]</xref>
###xml 243 248 243 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARMS2</italic>
###xml 480 484 480 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Fritsche1">[20]</xref>
###xml 545 549 545 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Kanda1">[33]</xref>
###xml 604 608 604 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Fritsche1">[20]</xref>
Strong linkage disequilibrium (LD) across the ARMS2-HTRA1 region makes it difficult to distinguish between ARMS2 [16], [17] and HTRA1[21], [22] as causal factors in AMD pathogenesis. We recently identified a deletion-insertion polymorphism in ARMS2 (*372_815del443ins54) that is in almost perfect LD with the A69S variant and directly affects the stability of the transcript by removing the polyadenylation signal and inserts a 54-bp element known to mediate rapid mRNA turnover. [20] Immunohistochemistry has associated ARMS2 with mitochondria [33], specifically within the photoreceptor inner segments [20], suggesting that mechanisms of mitochondrial dysfunction may be involved in AMD pathogenesis.
###end p 33
###begin p 34
###xml 13 17 13 17 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Bergmann1">[34]</xref>
###xml 31 35 31 35 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Holz3">[35]</xref>
###xml 196 200 196 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Zhou1">[36]</xref>
###xml 331 334 331 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 571 574 571 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 626 630 626 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Scholl3">[37]</xref>
###xml 890 894 890 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Magnusson1">[38]</xref>
###xml 918 921 918 921 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 923 925 923 925 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C3</italic>
###xml 931 936 931 936 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARMS2</italic>
###xml 1106 1110 1106 1110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Holz2">[28]</xref>
Experimental [34] and clinical [35] data propose a key role of the major lipofuscin fluorophore A2-E in GA progression. Interestingly, A2-E biogenesis was recently linked to complement activation [36]. There is now compelling evidence that the complement system is involved in the pathogenesis of AMD and that the Y402H variant of CFH is associated with AMD susceptibility. Our data confirm this finding specifically for GA. Recently, we have detected systemic complement activation in AMD and found that markers of chronic complement activation were associated with the CFH risk haplotype (including the Y402H polymorphism). [37] However, since the Y402H variant of CFH confers similar risk of soft drusen and both forms of advanced AMD, it may contribute to the increased risk of advanced AMD largely or entirely through its impact on precursors of visually disabling AMD such as drusen. [38] Since polymorphisms in CFH, C3, and ARMS2 are not associated with progression of GA and since our previous analysis did not detect a significant contribution of other characteristics (including smoking and BMI) [28] other modifying genetic factors may be involved.
###end p 34
###begin p 35
###xml 242 245 242 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 247 249 247 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C3</italic>
###xml 255 260 255 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARMS2</italic>
###xml 650 658 <span type="species:ncbi:9606">patients</span>
Our findings may have strong implications for future efforts to design therapeutic interventions for AMD, although replication in an independent cohort and empirical treatment data are needed for further substantiation. Since variants within CFH, C3, and ARMS2 confer risk for susceptibility of GA but appear unrelated to its progression, addressing the complement cascade or ARMS2-, and possibly HTRA1-associated pathways per se may not be promising strategies for alleviating disease progression once GA has developed. Instead, defining the exogenic and possibly the genetic factors responsible for GA progression could be crucial in helping those patients already suffering from advanced stages of the disease.
###end p 35
###begin title 36
Methods
###end title 36
###begin title 37
Ethics Statement
###end title 37
###begin p 38
###xml 186 193 <span type="species:ncbi:9606">patient</span>
The study followed the tenets of the Declaration of Helsinki and was approved by the local Ethics Review Board at the University of Bonn. Informed written consent was obtained from each patient after explanation of the nature and possible consequences of the study.
###end p 38
###begin title 39
Cases and Controls
###end title 39
###begin p 40
###xml 120 121 120 121 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</underline>
###xml 127 128 127 128 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</underline>
###xml 159 160 159 160 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</underline>
###xml 262 266 262 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Holz2">[28]</xref>
###xml 268 272 268 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Bindewald1">[39]</xref>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 288 296 <span type="species:ncbi:9606">patients</span>
Patients with GA secondary to AMD were included from the longitudinal natural history arm of the multicenter FAM-Study (Fundus Autofluorescence in Age-Related Macular Degeneration; registration : NCT00393692). The study procedures have been previously reported. [28], [39] A total of 619 patients with dry (early or late) AMD in the study eye were enrolled (mean age, 73.9 years; mean follow-up, 35 months) and were recruited at six centres throughout Germany. Because of differences in genotype frequencies due to race and geographical origin, only white probands originating exclusively from Germany were included in the study.
###end p 40
###begin p 41
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients with uni- or multifocal GA and with clear vitreous to allow FAF imaging were included in the analysis. Exclusion criteria were a history of retinal surgery, laser photocoagulation and radiation therapy or other retinal diseases in the study eye such as diabetic retinopathy or hereditary retinal dystrophies. Fluorescein angiography was only performed if funduscopic signs were present indicative of neovascular AMD in addition to patches of GA. Such eyes were excluded from further analysis.
###end p 41
###begin p 42
###xml 177 181 177 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Rivera1">[17]</xref>
###xml 321 329 <span type="species:ncbi:9606">Patients</span>
612 unrelated control individuals of German origin served as controls for case-control analysis to investigate the role of variants in CFH, C3 and ARMS2 for AMD susceptibility. [17] Each control subject underwent a single ophthalmic examination including visual acuity, slit lamp biomicroscopy and fundus ophthalmoscopy. Patients and controls underwent a general health interview protocol including a standardized smoking history.
###end p 42
###begin title 43
Phenotyping by FAF Imaging
###end title 43
###begin p 44
###xml 248 252 248 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Holz4">[40]</xref>
###xml 832 836 820 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-SchmitzValckenberg1">[41]</xref>
FAF was measured using a confocal laser scanning ophthalmoscope (cSLO; Heidelberg Retina Angiograph, HRA classic and HRA 2, Heidelberg Engineering, Dossenheim, Germany), the optical and technical principles of which have been described previously. [40] An argon blue laser (HRA classic) or optically pumped solid state laser (HRA 2) were used for excitation (both 488 nm). The emitted light above 500 nm was detected with a barrier filter. FAF images were recorded in accordance with standard operating procedures (SOP) including focussing in the blue reflection mode, acquisition of a series of 30degreesx30degrees images (488 nm) and calculation of mean images after automated alignment in order to amplify signal to noise ratio with image analysis software (Heidelberg Eye Explorer, Heidelberg Engineering, Dossenheim, Germany). [41]
###end p 44
###begin p 45
###xml 217 221 217 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Holz2">[28]</xref>
###xml 223 227 223 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Dreyhaupt1">[32]</xref>
###xml 573 577 573 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Deckert1">[42]</xref>
###xml 670 671 670 671 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 711 715 711 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Dreyhaupt1">[32]</xref>
###xml 727 728 727 728 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 5 12 <span type="species:ncbi:9606">patient</span>
Only patient eyes with at least two follow-ups in a 6 month interval and with sufficient image quality to accurately determine the size of atrophy were included. To further improve on our previous analytical strategy [28], [32], serial FAF images of the same eye were aligned by the "4-point-alignment" function using Picture Window Pro 4.0.1.2 analysis software (Digital Light & Color, Cambridge, MA, USA). The total size of GA was measured in the processed FAF images by automated imaging analysis software that uses region-growing techniques to segment the areas of GA. [42] This procedure significantly reduced the estimated within-group error variance from 0.761 mm2/year, 95% CI [0.645; 0.898] previously [32] to 0.212 mm2/year, 95% CI [0.182; 0.246].
###end p 45
###begin title 46
Genotyping
###end title 46
###begin p 47
Genomic DNA was extracted from peripheral blood leukocytes according to established protocols. Genotyping was done by TaqMan SNP Genotyping or by the matrix-assisted laser desorption/ionization time of flight (MALDI-TOF) mass spectrometry method (Sequenom, San Diego, CA, USA). TaqMan Pre-Designed SNP Genotyping Assays (Applied Biosystems, Foster City, CA, USA) were performed according to the manufacturer's instructions and were analyzed with a 7900HT Fast Real-Time PCR System (Applied Biosystems). All SNPs showed high genotyping quality with an average call rate of 98.5%.
###end p 47
###begin title 48
Statistical Analysis
###end title 48
###begin p 49
###xml 431 435 431 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Dreyhaupt1">[32]</xref>
###xml 437 441 437 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Dreyhaupt2">[43]</xref>
###xml 868 872 868 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Dreyhaupt1">[32]</xref>
###xml 514 521 <span type="species:ncbi:9606">patient</span>
###xml 851 858 <span type="species:ncbi:9606">patient</span>
Data management and statistical analysis were conducted using SAS Version 9.1.3 (Cary, NC, USA). The statistical analyses were carried out using software package R, Version 2.7.0 (), and the R-library "non-linear mixed effects" (NLME) was applied for hierarchical regression modelling. A linear mixed effects model was used to quantify GA growth. A detailed description of the longitudinal modelling process is provided elsewhere. [32], [43] The two-level-random effects model separates ocular-specific as well as patient-specific effects and helps to handle related observations. The mixed model methodology allows the study of variance components and fixed effects simultaneously. Using this two-level-random effects model, a single variable of GA progression rate was computed based on longitudinal observations of either one or both eyes for each patient studied. [32] This variable represents a continuous, biology-based quantitative phenotype and was used for association analysis with genetic data.
###end p 49
###begin p 50
###xml 94 98 94 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Becker1">[44]</xref>
###xml 225 229 225 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007418-Dudbridge1">[45]</xref>
We used the case-control tool box from FAMHAP to perform quality control of the genetic data. [44] SNP genotypes in cases and controls showed no deviation from Hardy-Weinberg-Equilibrium at a level of alpha = 0.001. UNPHASED [45] was used to test for association between the quantitative trait variable "GA progression" and SNP alleles and haplotypes. We adopted the standard practice of genetic epidemiological studies to test in an allele-based manner when the underlying disease model is unknown. This has the advantage of reducing the number of degrees of freedom to 1. Although the resulting test is additive by nature, it is the most powerful test under a much broader range of true disease scenarios. The UNPHASED program provides P values as well as additive effect estimators for the effects of alleles/haplotypes on the quantitative trait. The reference alleles represent the respective major SNP alleles within Caucasian populations. The respective confidence intervals are provided as well. We also adjusted for the covariates age, BMI, and smoking, using the "modifiers" option of the UNPHASED software package. Posthoc power values for a t-test as an approximation of power for quantitative trait analysis for single SNPs were computed with the R software package, with the two groups of the t-test constituting the two alleles and the group sizes the allele counts. Covariates were not accounted for in the power calculation. Since the disease-associated allele is known, one-sided power values were computed.
###end p 50
###begin title 51
Supporting Information
###end title 51
###begin p 52
###xml 46 54 <span type="species:ncbi:9606">patients</span>
Clinical and molecular genetic findings in 99 patients with late-stage AMD
###end p 52
###begin p 53
(0.27 MB DOC)
###end p 53
###begin p 54
Click here for additional data file.
###end p 54
###begin p 55
Power values for alpha = 0.05 and additive allele effects of growth of geographic atrophy (n = 99)
###end p 55
###begin p 56
(0.04 MB DOC)
###end p 56
###begin p 57
Click here for additional data file.
###end p 57
###begin p 58
###xml 23 31 <span type="species:ncbi:9606">patients</span>
We are grateful to the patients and control subjects for their participation in this study.
###end p 58
###begin title 59
References
###end title 59
###begin article-title 60
Causes and prevalence of visual impairment among adults in the United States.
###end article-title 60
###begin article-title 61
Age-related macular degeneration.
###end article-title 61
###begin article-title 62
Pathogenesis of lesions in late age-related macular disease.
###end article-title 62
###begin article-title 63
Age-related macular degeneration.
###end article-title 63
###begin article-title 64
Prevalence of age-related macular degeneration in the United States.
###end article-title 64
###begin article-title 65
Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study.
###end article-title 65
###begin article-title 66
The epidemiology of age-related macular degeneration.
###end article-title 66
###begin article-title 67
Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
###end article-title 67
###begin article-title 68
Ranibizumab for neovascular age-related macular degeneration.
###end article-title 68
###begin article-title 69
The genetics of age-related macular degeneration: a review of progress to date.
###end article-title 69
###begin article-title 70
An update on the genetics of age-related macular degeneration.
###end article-title 70
###begin article-title 71
Complement factor H polymorphism and age-related macular degeneration.
###end article-title 71
###begin article-title 72
A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration.
###end article-title 72
###begin article-title 73
Complement factor H variant increases the risk of age-related macular degeneration.
###end article-title 73
###begin article-title 74
Complement factor H polymorphism in age-related macular degeneration.
###end article-title 74
###begin article-title 75
Susceptibility genes for age-related maculopathy on chromosome 10q26.
###end article-title 75
###begin article-title 76
Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk.
###end article-title 76
###begin article-title 77
Variation in complement factor 3 is associated with risk of age-related macular degeneration.
###end article-title 77
###begin article-title 78
Complement C3 variant and the risk of age-related macular degeneration.
###end article-title 78
###begin article-title 79
Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA.
###end article-title 79
###begin article-title 80
HTRA1 promoter polymorphism in wet age-related macular degeneration.
###end article-title 80
###begin article-title 81
A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration.
###end article-title 81
###begin article-title 82
Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration.
###end article-title 82
###begin article-title 83
The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No. 17.
###end article-title 83
###begin article-title 84
Measuring geographic atrophy in advanced age-related macular degeneration.
###end article-title 84
###begin article-title 85
Prospective evaluation of digital non-stereo color fundus photography as a screening tool in age-related macular degeneration.
###end article-title 85
###begin article-title 86
Inter- and intra-observer variability in grading lesions of age-related maculopathy and macular degeneration.
###end article-title 86
###begin article-title 87
Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration.
###end article-title 87
###begin article-title 88
A concordance correlation coefficient to evaluate reproducibility.
###end article-title 88
###begin article-title 89
A prospective study of 2 major age-related macular degeneration susceptibility alleles and interactions with modifiable risk factors.
###end article-title 89
###begin article-title 90
Change in Area of Geographic Atrophy in the Age-Related Eye Disease Study: AREDS Report Number 26.
###end article-title 90
###begin article-title 91
###xml 55 63 <span type="species:ncbi:9606">patients</span>
Modelling the natural history of geographic atrophy in patients with age-related macular degeneration.
###end article-title 91
###begin article-title 92
A variant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is strongly associated with age-related macular degeneration.
###end article-title 92
###begin article-title 93
Inhibition of the ATP-driven proton pump in RPE lysosomes by the major lipofuscin fluorophore A2-E may contribute to the pathogenesis of age-related macular degeneration.
###end article-title 93
###begin article-title 94
Fundus autofluorescence and development of geographic atrophy in age-related macular degeneration.
###end article-title 94
###begin article-title 95
Complement activation by photooxidation products of A2E, a lipofuscin constituent of the retinal pigment epithelium.
###end article-title 95
###begin article-title 96
Systemic complement activation in age-related macular degeneration.
###end article-title 96
###begin article-title 97
CFH Y402H confers similar risk of soft drusen and both forms of advanced AMD.
###end article-title 97
###begin article-title 98
###xml 108 116 <span type="species:ncbi:9606">patients</span>
Classification of abnormal fundus autofluorescence patterns in the junctional zone of geographic atrophy in patients with age related macular degeneration.
###end article-title 98
###begin article-title 99
Simultaneous confocal scanning laser fluorescein and indocyanine green angiography.
###end article-title 99
###begin article-title 100
###xml 93 101 <span type="species:ncbi:9606">patients</span>
Fundus autofluorescence and fundus perimetry in the junctional zone of geographic atrophy in patients with age-related macular degeneration.
###end article-title 100
###begin article-title 101
Automated analysis of digital fundus autofluorescence images of geographic atrophy in advanced age-related macular degeneration using confocal scanning laser ophthalmoscopy (cSLO).
###end article-title 101
###begin article-title 102
###xml 69 77 <span type="species:ncbi:9606">patients</span>
Discovery of factors influencing the growth of geographic atrophy in patients with age-related macular degeneration.
###end article-title 102
###begin article-title 103
Multiple testing in the context of haplotype analysis revisited: application to case-control data.
###end article-title 103
###begin article-title 104
Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data.
###end article-title 104
###begin p 105
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 105
###begin p 106
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported in part by grants from the European Commission (EU FP6) (HPNS, FGH), the Integrated Project "EVIGENORET" (LSHG-CT-2005-512036) (HPNS, FGH); the German Research Foundation (DFG) Heisenberg Fellowship SCHO 734/2-1 (HPNS); the DFG Priority Research Programme Age-related Macular Degeneration (SPP1088) (FGH); DFG grants HO1926/1-3 (FGH); WE1259/18-1 (BHFW), and WE1259/19-1 (BHFW), a Research Grant from the German Society of Ophthalmology (DOG) 2006/2007 (MF); the Kroener Foundation (Germering, Germany); The Ruth and Milton Steinbach Foundation New York (BHFW) and the Alcon Research Institute (BHFW). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 106

